BL BioAge Labs, Inc. Stock: price and insider trades · United States · SEC (Form 4)Track the BioAge Labs, Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €480.1m. The latest transaction was filed on 1 July 2026 (Levée d'options). Among the most active insiders: Barton Shane. Every trade is free.
Analyst consensus: bullish or bearish? Analysts rate BioAge Labs, Inc. Buy (bullish), based on 8 analysts. Average price target: US$35.63.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 July 2026
All Executives33 Thresholds0 Prospectus0 Other0
Declarations 33 total
◇ Principal Accounting Officer · Executives · 29 Jun 2026
9,301 shares Common Stock SEC:0001836297-26-000005:0
◇ Principal Accounting Officer · Executives · 29 Jun 2026
7,261 shares Common Stock SEC:0001836297-26-000005:1
◇ Principal Accounting Officer · Executives · 29 Jun 2026
8,958 shares Common Stock SEC:0001836297-26-000005:2
◇ Principal Accounting Officer · Executives · 29 Jun 2026
14,198 shares Common Stock SEC:0001836297-26-000005:3
▼ Principal Accounting Officer · Executives · 29 Jun 2026
42,350 shares Common Stock SEC:0001836297-26-000005:4
◇ Principal Accounting Officer · Executives · 30 Jun 2026
4,290 shares Common Stock SEC:0001836297-26-000005:5
◇ Principal Accounting Officer · Executives · 30 Jun 2026
4,000 shares Common Stock SEC:0001836297-26-000005:6
◇ Principal Accounting Officer · Executives · 30 Jun 2026
4,065 shares Common Stock SEC:0001836297-26-000005:7
◇ Principal Accounting Officer · Executives · 30 Jun 2026
7,861 shares Common Stock SEC:0001836297-26-000005:8
▼ Principal Accounting Officer · Executives · 30 Jun 2026
20,216 shares Common Stock SEC:0001836297-26-000005:9
● Officer · Executives · 30 Jun 2026
20,216 shares @ US$25.1868 0.049% mcap 31.3% of flow Common SEC144:0001959173-26-004979
● Officer · Executives · 29 Jun 2026
42,350 shares @ US$25.2084 0.10% mcap 65.7% of flow Common SEC144:0001959173-26-004955
◇ Chief Financial Officer · Executives · 23 Apr 2026
3,542 shares @ US$4.38 0.0014% mcap 100.0% of flow Common Stock SEC:0001120478-26-000013:0
◇ Chief Medical Officer · Executives · 1 Apr 2026
5,437 shares @ US$4.11 11.1% of flow Common Stock SEC:0001210905-26-000011:0
◇ Chief Medical Officer · Executives · 1 Apr 2026
3,383 shares @ US$6.57 11.0% of flow Common Stock SEC:0001210905-26-000011:1
▼ Chief Medical Officer · Executives · 1 Apr 2026
8,820 shares @ US$17.81 77.9% of flow Common Stock SEC:0001210905-26-000011:2
◇ Chief Medical Officer · Executives · 2 Mar 2026
5,433 shares @ US$4.11 3.3% of flow Common Stock SEC:0001210905-26-000009:0
◇ Chief Financial Officer · Executives · 1 Mar 2026
3,542 shares @ US$4.38 5.3% of flow Common Stock SEC:0001120478-26-000011:0
◇ Chief Financial Officer · Executives · 1 Feb 2026
3,541 shares @ US$4.38 5.2% of flow Common Stock SEC:0001120478-26-000007:0
◇ Chief Medical Officer · Executives · 2 Feb 2026
5,433 shares @ US$4.11 3.3% of flow Common Stock SEC:0001210905-26-000005:0
◇ Chief Financial Officer · Executives · 16 Jan 2026
3,542 shares @ US$4.38 5.4% of flow Common Stock SEC:0001120478-26-000005:0
▼ Chief Executive Officer · Executives · 13 Jan 2026
233,107 shares @ US$18.1163 100.0% of flow Common Stock SEC:0002032751-26-000003:0
◇ Chief Financial Officer · Executives · 13 Jan 2026
27,000 shares @ US$8.39 78.6% of flow Common Stock SEC:0001120478-26-000003:0
◇ Chief Medical Officer · Executives · 2 Jan 2026
5,433 shares @ US$4.11 3.3% of flow Common Stock SEC:0001210905-26-000002:0
◇ Chief Medical Officer · Executives · 9 Dec 2025
18,000 shares @ US$6.57 19.6% of flow Common Stock SEC:0001210905-25-000006:0
25 of 33 declarations
Load more (8 remaining) 关于 BioAge Labs, Inc. BioAge Labs, Inc. 是一家生物技术公司，专注于通过靶向衰老机制来开发延长寿命的疗法。该公司在 XNAS 市场上市。